Nature Reviews Urology最新文献_第8页

Increased xenokidney survival 提高异种肾存活率

IF 12.1 1区医学

Nature Reviews Urology Pub Date : 2024-07-15 DOI: 10.1038/s41585-024-00918-3

Louise Lloyd

引用次数: 0

Alternative promoters activate oncogenic programmes 替代启动子激活致癌程序

IF 12.1 1区医学

Nature Reviews Urology Pub Date : 2024-07-12 DOI: 10.1038/s41585-024-00919-2

Louise Lloyd

引用次数: 0

Microplastics in the penis 阴茎中的微塑料

IF 12.1 1区医学

Nature Reviews Urology Pub Date : 2024-07-12 DOI: 10.1038/s41585-024-00917-4

Louise Lloyd

引用次数: 0

Optimizing cystoscopy and TURBT: enhanced imaging and artificial intelligence. 优化膀胱镜检查和 TURBT：增强成像和人工智能。

IF 12.1 1区医学

Nature Reviews Urology Pub Date : 2024-07-09 DOI: 10.1038/s41585-024-00904-9

Eugene Shkolyar, Steve R Zhou, Camella J Carlson, Shuang Chang, Mark A Laurie, Lei Xing, Audrey K Bowden, Joseph C Liao

引用次数: 0

Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer. 前列腺癌中 PSMA 表达、调节和异质性的生物学决定因素。

IF 12.1 1区医学

Nature Reviews Urology Pub Date : 2024-07-08 DOI: 10.1038/s41585-024-00900-z

Martin K Bakht, Himisha Beltran

{"title":"Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer.","authors":"Martin K Bakht, Himisha Beltran","doi":"10.1038/s41585-024-00900-z","DOIUrl":"https://doi.org/10.1038/s41585-024-00900-z","url":null,"abstract":"Prostate-specific membrane antigen (PSMA) is an important cell-surface imaging biomarker and therapeutic target in prostate cancer. The PSMA-targeted theranostic 177Lu-PSMA-617 was approved in 2022 for men with PSMA-PET-positive metastatic castration-resistant prostate cancer. However, not all patients respond to PSMA-radioligand therapy, in part owing to the heterogeneity of PSMA expression in the tumour. The PSMA regulatory network is composed of a PSMA transcription complex, an upstream enhancer that loops to the FOLH1 (PSMA) gene promoter, intergenic enhancers and differentially methylated regions. Our understanding of the PSMA regulatory network and the mechanisms underlying PSMA suppression is evolving. Clinically, molecular imaging provides a unique window into PSMA dynamics that occur on therapy and with disease progression, although challenges arise owing to the limited resolution of PET. PSMA regulation and heterogeneity - including intertumoural and inter-patient heterogeneity, temporal changes, lineage dynamics and the tumour microenvironment - affect PSMA theranostics. PSMA response and resistance to radioligand therapy are mediated by a number of potential mechanisms, and complementary biomarkers beyond PSMA are under development. Understanding the biological determinants of cell surface target regulation and heterogeneity can inform precision medicine approaches to PSMA theranostics as well as other emerging therapies.","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":" ","pages":""},"PeriodicalIF":12.1,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141559327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Author Correction: Advances in sliding clip renorrhaphy for partial nephrectomy 作者更正：用于肾部分切除术的滑动夹肾切除术的进展。

IF 12.1 1区医学

Nature Reviews Urology Pub Date : 2024-07-05 DOI: 10.1038/s41585-024-00915-6

David Homewood, Tayla Fay, Nicholas Tan, Andrew Silagy, Niall M. Corcoran, Nathan Lawrentschuk, Dinesh Agarwal

引用次数: 0

CRISPR-Cas9 potential for identifying novel therapeutic targets in muscle-invasive bladder cancer. CRISPR-Cas9 在确定肌肉浸润性膀胱癌新治疗靶点方面的潜力。

IF 12.1 1区医学

Nature Reviews Urology Pub Date : 2024-07-01 DOI: 10.1038/s41585-024-00901-y

Danielle J Smith, Sapna Lunj, Antony D Adamson, Sankari Nagarajan, Tim A D Smith, Kimberley J Reeves, Peter J Hoskin, Ananya Choudhury

{"title":"CRISPR-Cas9 potential for identifying novel therapeutic targets in muscle-invasive bladder cancer.","authors":"Danielle J Smith, Sapna Lunj, Antony D Adamson, Sankari Nagarajan, Tim A D Smith, Kimberley J Reeves, Peter J Hoskin, Ananya Choudhury","doi":"10.1038/s41585-024-00901-y","DOIUrl":"https://doi.org/10.1038/s41585-024-00901-y","url":null,"abstract":"Gene editing technologies help identify the genetic perturbations driving tumour initiation, growth, metastasis and resistance to therapeutics. This wealth of information highlights tumour complexity and is driving cancer research towards precision medicine approaches based on an individual's tumour genetics. Bladder cancer is the 11th most common cancer in the UK, with high rates of relapse and low survival rates in patients with muscle-invasive bladder cancer (MIBC). MIBC is highly heterogeneous and encompasses multiple molecular subtypes, each with different responses to therapeutics. This evidence highlights the need to identify innovative therapeutic targets to address the challenges posed by this heterogeneity. CRISPR-Cas9 technologies have been used to advance our understanding of MIBC and determine novel drug targets through the identification of drug resistance mechanisms, targetable cell-cycle regulators, and novel tumour suppressor and oncogenes. However, the use of these technologies in the clinic remains a substantial challenge and will require careful consideration of dosage, safety and ethics. CRISPR-Cas9 offers considerable potential for revolutionizing bladder cancer therapies, but substantial research is required for validation before these technologies can be used in the clinical setting.","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":" ","pages":""},"PeriodicalIF":12.1,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141477033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

De-clear cell differentiated renal cell carcinoma — a new therapeutic target 去透明细胞分化型肾细胞癌--新的治疗目标

IF 15.3 1区医学

Nature Reviews Urology Pub Date : 2024-06-27 DOI: 10.1038/s41585-024-00911-w

Keith A. Lawson, W. Marston Linehan

引用次数: 0

Advances in sliding clip renorrhaphy for partial nephrectomy 用于肾部分切除术的滑动夹式肾切除术的进展。

IF 12.1 1区医学

Nature Reviews Urology Pub Date : 2024-06-25 DOI: 10.1038/s41585-024-00906-7

David Homewood, Tayla Fay, Nicholas Tan, Andrew Silagy, Niall M. Corcoran, Nathan Lawrentschuk, Dinesh Agarwal

引用次数: 0

Renal mass biopsy - a practical and clinicopathologically relevant approach to diagnosis. 肾肿块活检--一种实用且与临床病理相关的诊断方法。

IF 12.1 1区医学

Nature Reviews Urology Pub Date : 2024-06-21 DOI: 10.1038/s41585-024-00897-5

Hussein Mansour, My-Anh Tran-Dang, Miles Walkden, Ekaterini Boleti, Ravi Barod, Prasad Patki, Faiz Mumtaz, Maxine G B Tran, Axel Bex, Soha El Sheikh

{"title":"Renal mass biopsy - a practical and clinicopathologically relevant approach to diagnosis.","authors":"Hussein Mansour, My-Anh Tran-Dang, Miles Walkden, Ekaterini Boleti, Ravi Barod, Prasad Patki, Faiz Mumtaz, Maxine G B Tran, Axel Bex, Soha El Sheikh","doi":"10.1038/s41585-024-00897-5","DOIUrl":"https://doi.org/10.1038/s41585-024-00897-5","url":null,"abstract":"Advancements in imaging modalities have increased the frequency of renal mass discovery. Imaging has typically been considered sufficient to guide management for a large proportion of these tumours, but renal mass biopsies (RMBs) have an increasing role in determining malignancy and can be a valuable tool for preventing unnecessary surgery in patients with benign tumours. A structured approach should be used to help to navigate the expanding repertoire of renal tumours, many of which are molecularly defined. In terms of tumour subtyping, the pathologist's strategy should focus on stratifying patients into clinically different prognostic groups according to our current knowledge of tumour behaviour, including benign, low-grade or indolent, intermediate malignant or highly aggressive. Crucial pathological features and morphological mimicry of tumours can alter the tumour's prognostic group. Thus, pathologists and urologists can use RMB to select patients with tumours at a reduced risk of progression, which can be safely managed with active surveillance within a tailored imaging schedule, versus tumours for which ablation or surgical intervention is indicated. RMB is also crucial in the oncological setting to distinguish between different high-grade tumours and guide tailored management strategies.","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":" ","pages":""},"PeriodicalIF":12.1,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141437223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0